Article
Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
Archives of internal medicine - 1 Oct 1991
Caporaso N E, Shaw G L
Abstract excerpt
Approximately 10% of western populations are genetically deficient in the enzyme that metabolizes the antihypertensive drug debrisoquin. These "poor metabolizers" process many common medications in an aberrant fashion, resulting in a variety of untoward consequences including exaggerated drug effect, subtherapeutic drug concentrations, or complex drug interactions. A variety of medications, including...
Topics
- Adrenergic beta-Antagonists
- Anti-Arrhythmia Agents
- Antidepressive Agents, Tricyclic
- Antihypertensive Agents
- Antipsychotic Agents
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme System
- Drug Interactions
- Humans